Managing HIV Patients with Limited Treatment Options 2022
Related Enduring Materials
Program
Welcome
Despite improved antiretroviral regimens, virological failure and the emergence of drug resistance remains an ongoing challenge throughout Europe. This includes both patients who recently contracted the virus as well as veterans of older regimens. Although the resources, diagnostics, and soon drugs, required for the improved care of complex patients are now available in many parts of Europe, there remains a knowledge gap in how to best use them. Acquiring and interpreting resistance data correctly, incorporating co-morbidities and co-medications data, and then deciding on the optimal next regimen for patients with limited treatment options requires a high level of expertise. Managing these complex HIV patients requires greater knowledge and understanding in terms of adherence, resistance, aging, comorbidities, and polypharmacy.
This webinar has been designed for HIV physicians who would like to improve their knowledge of identifying and managing patients with limited treatment options, as well as new antiretroviral drugs for optimizing the treatment of these patients.
Program Chairs
General Information
Specifically:
- HIV physicians experienced in treating treatment-experienced patients with HIV who need to be informed and updated on new treatment options;
- HIV physicians inexperienced in treating complex HIV patients who need a more comprehensive education on identifying and managing treatment-experienced patients with an emphasis on new drugs;
- Clinical pharmacologists involved in the concomitant medication management and dose adjusting for co-morbidities of the treatment-experienced patient with HIV; and
- Other healthcare professionals (e.g. nurse practitioners) intimately involved in the medical care of treatment-experienced patients.
- Improved knowledge of the definition of treatment-experienced people living with HIV and the challenges of their care;
- Acquired tools and understanding on how best to Identify the treatment-experienced HIV patient in their clinical practice;
- Greater understanding of the new treatment options available for these patients, including recently presented clinical trials;
- Learned how best to integrate these new drugs into optimal combination regimens for treatment-experienced patients, considering their local country setting; and
- Improved their skills in managing drug-drug interactions and toxicities in these treatment-experienced patients.
Practical Information
Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Become an Endorser
If you would like your organization to support the Liverpool Course as an endorser or media partner, please contact Brenda Evan at Brenda.Evan@amededu.com.
The Managing HIV Patients With Limited Treatment Options symposium is supported by an independent educational grant from ViiV Healthcare.
ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Support Our Initiative
Financial backing helps us deliver an impactful meeting experience to the benefit of healthcare professionals.
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
To show your commitment to the cause, get in touch with us for a tailored
support package by contacting Brenda at Brenda.Evan@amededu.com or call +31 30 230 7149.
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.
- Symposium opportunities
- Non-commercial interviews with company representatives
- Verbal acknowledgement during the program
- Discounted and complimentary registrations for your representatives
- Company acknowledgement on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
- Company acknowledgement on printed meeting materials including but not limited to banners and the program book
- Digital and printed advertising opportunities
- Social media shout-outs
- Logo on the conference bag
*Subject to the support level.
Accreditation Statement
Managing HIV Patients with Limited Treatment Options 2022, Glasgow, United Kingdom, 22/10/2022-22/10/202 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 2 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Managing HIV Patients With Limited Treatment Options 2021
Top-Rated Materials from Previous Editions
Andrea Calcagno - Pharmacological Considerations in Optimizing Care for Patients
Managing HIV Patients with Limited Treatment Options 2021
Health & Safety Measures regarding COVID-19
Ensuring the health and safety of our attendees, suppliers, and staff is our absolute number one priority. In order to provide a safe conference environment, all hybrid and live events organized by Virology Education will follow the national health and safety measures of the country where the meeting is being held in. We kindly ask that all attendees carefully abide by these measures to assist us in ensuring a safe environment for all.
National Health & Safety Measures
The health and safety measures that will be taken by Virology Education during the Managing HIV Patients With Limited Treatment Options 2022 are listed below. Please read them very carefully before traveling to the conference venue. These measures will be reviewed in accordance with the evolution of the pandemic.
Our staff will be available onsite to address any questions or concerns that you might have. If you have any questions in advance, please contact the Conference Secretariat at Brenda.Evan@amededu.com
Traveling to United Kingdom
Virology Education strongly advises participants to check the government website of the United Kingdom (https://www.gov.uk/uk-border-control) for the latest and most accurate information about the rules regarding travel.
Traveling to the United kingdom
- For example: Please check if you have been in a country or territory that is mentioned on the Red List during the two weeks prior to your arrival in the UK. Certain quarantine rules may apply.
- For example: Please be aware of the vaccine restrictions for the UK. Before traveling, check that the vaccine you have received is on Uk’s approved list.
Access to the Conference Venue
Face Masks
Attendees are strongly encouraged to wear a face mask in the venue. Wearing a face mask will not be mandatory in the areas that are designated to the consumption of food and beverages.
Hand Sanitizer
Multiple hand sanitizer stations will be set up throughout the conference venue. Please make sure to use them regularly.
Liability Waiver
Virology Education cannot guarantee that its participants, volunteers, partners, or others in attendance will not become infected with COVID-19.
To the maximum extent permitted by law, Virology Education accepts no liability for any illness, COVID-19 related or otherwise, that may subsequently be contracted after or during the event.
All participants acknowledge and agree that they are attending the event at their own risk
